Pfizer to close Mumbai manufacturing facility

With no active production at the plant since 2013, the company said it would shutter its Mumbai, India-based facility in mid-September, according to a Bombay Stock Exchange filing. 

The decision to close the Plant is based on an assessment of its long term viability and its ability to achieve the needed production,” Pfizer said. “There has practically been no production activity at this plant since 2013, and the closure will not impact the supply of any of the Company's medicines to patients.”

All of Pfizers' employees at the 50-year-old plant were offered a voluntary retirement scheme last year, and 132 out of 212 took the option. The company said the remaining workers continue to receive full wages despite the plant’s inactivity.

The closure comes as Pfizer’s recent acquisition of Hospira brings along with it an injectables plant in the Andhra Pradesh region of India, which earlier this month got the go-ahead from the FDA to begin commercial production.